Tags

Type your tag names separated by a space and hit enter

The endocannabinoid system in gp120-mediated insults and HIV-associated dementia.

Abstract

Endocannabinoids (eCBs) include a group of lipid mediators that act as endogenous agonists at cannabinoid (CB(1), CB(2)) and vanilloid (TRPV1) receptors. In the last two decades a number of eCBs-metabolizing enzymes have been discovered that, together with eCBs and congeners, target receptors and proteins responsible for their transport and intracellular trafficking form the so-called "endocannabinoid system" (ECS). Within the central nervous system ECS elements participate in neuroprotection against neuroinflammatory/neurodegenerative diseases like Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis. More recently, a role for eCBs has been documented also in human immunodeficiency virus-1 (HIV-1) envelope glycoprotein gp120-mediated insults, and in HIV-associated dementia (HAD). The modulation of ECS in the latter disease conditions is the subject of this review, that will also address the molecular mechanisms underlying the neuroprotective effects of eCBs. In particular, the interactions between neurons and glia during neuroinflammation, and the alterations of ECS in these cells upon gp120 insults and HAD will be discussed, along with the potential therapeutic exploitation of ECS-oriented drugs for the treatment of HAD and related disorders.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome, Italy.

    , ,

    Source

    Experimental neurology 224:1 2010 Jul pg 74-84

    MeSH

    AIDS Dementia Complex
    Animals
    Brain
    Cannabinoid Receptor Modulators
    Cytoprotection
    Endocannabinoids
    HIV Envelope Protein gp120
    Humans
    Neurodegenerative Diseases
    Neurons
    Receptors, Cannabinoid
    Signal Transduction

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    20353779

    Citation

    Bari, Monica, et al. "The Endocannabinoid System in Gp120-mediated Insults and HIV-associated Dementia." Experimental Neurology, vol. 224, no. 1, 2010, pp. 74-84.
    Bari M, Rapino C, Mozetic P, et al. The endocannabinoid system in gp120-mediated insults and HIV-associated dementia. Exp Neurol. 2010;224(1):74-84.
    Bari, M., Rapino, C., Mozetic, P., & Maccarrone, M. (2010). The endocannabinoid system in gp120-mediated insults and HIV-associated dementia. Experimental Neurology, 224(1), pp. 74-84. doi:10.1016/j.expneurol.2010.03.025.
    Bari M, et al. The Endocannabinoid System in Gp120-mediated Insults and HIV-associated Dementia. Exp Neurol. 2010;224(1):74-84. PubMed PMID: 20353779.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - The endocannabinoid system in gp120-mediated insults and HIV-associated dementia. AU - Bari,Monica, AU - Rapino,Cinzia, AU - Mozetic,Pamela, AU - Maccarrone,Mauro, Y1 - 2010/03/29/ PY - 2010/4/1/entrez PY - 2010/4/1/pubmed PY - 2010/6/29/medline SP - 74 EP - 84 JF - Experimental neurology JO - Exp. Neurol. VL - 224 IS - 1 N2 - Endocannabinoids (eCBs) include a group of lipid mediators that act as endogenous agonists at cannabinoid (CB(1), CB(2)) and vanilloid (TRPV1) receptors. In the last two decades a number of eCBs-metabolizing enzymes have been discovered that, together with eCBs and congeners, target receptors and proteins responsible for their transport and intracellular trafficking form the so-called "endocannabinoid system" (ECS). Within the central nervous system ECS elements participate in neuroprotection against neuroinflammatory/neurodegenerative diseases like Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis. More recently, a role for eCBs has been documented also in human immunodeficiency virus-1 (HIV-1) envelope glycoprotein gp120-mediated insults, and in HIV-associated dementia (HAD). The modulation of ECS in the latter disease conditions is the subject of this review, that will also address the molecular mechanisms underlying the neuroprotective effects of eCBs. In particular, the interactions between neurons and glia during neuroinflammation, and the alterations of ECS in these cells upon gp120 insults and HAD will be discussed, along with the potential therapeutic exploitation of ECS-oriented drugs for the treatment of HAD and related disorders. SN - 1090-2430 UR - https://www.unboundmedicine.com/medline/citation/20353779/The_endocannabinoid_system_in_gp120_mediated_insults_and_HIV_associated_dementia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014-4886(10)00110-X DB - PRIME DP - Unbound Medicine ER -